PC:TIMBE

Timberlyne Therapeutics

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune disorders. The company is advancing CM313, a monoclonal antibody targeting CD38, aimed at addressing diseases with high unmet medical needs. Formed through a partnership between Mountainfield Venture Partners and Keymed Biosciences, Timberlyne Therapeutics holds global development and commercial rights for CM313 outside of greater China.

Leadership & Board

Key Executives

Most Popular Private Companies

Related News and Analysis